Register / Log in
Live Now

Browse a library of past webcasts and educational expert-led eLearning videos at your convenience.

Past Webcasts

../assets/websitedata/webcast.gw-pharma.com/Files/201218_Webcast10dec.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 10 December 2020

All

0

>

Welcome, introduction and agenda

307

Managing adverse events with GW CBD: behavioural and cognitive problems

1226

Managing adverse events with GW CBD: behavioural and cognitive problems (discussion)

1433

Implications of polytherapy in LGS for GW CBD

2206

Implications of polytherapy in LGS for GW CBD (discussion)

2512

Syndromic diagnosis of LGS

3673

Syndromic diagnosis of LGS (discussion)

4429

Meeting close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 10 December 2020

This webcast focused on the diagnosis and management of patients with LGS. The expert faculty discussed:

 

  • The importance of diagnosis in patients with LGS, including syndromic diagnoses
  • Cognitive and behavioural problems in patients with LGS receiving GW CBD
  • How to best manage polytherapy in patients with LGS receiving GW CBD
  • The evolution of LGS and implications for treatment, as well as diagnosis in adult patients
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 10 December 2020

../assets/websitedata/webcast.gw-pharma.com/Files/webcast4.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020

All

0

>

Welcome and introduction

289

Initiating patients with GW CBD (case studies)

1242

Initiating patients with GW CBD (discussion)

1540

Managing adverse events (case studies)

1993

Managing adverse events (discussion)

2365

Determining the optimal dose of GW CBD (case studies)

3130

Determining the optimal dose of GW CBD (discussion)

3379

Initiating GW CBD in patients who have previously received non-regulatory approved cannabis-based products (case studies)

3790

Initiating GW CBD in patients who have previously received non-regulatory approved cannabis-based products (discussion)

4030

Panel discussion: Early versus late intervention with GW CBD

4560

Summary and close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020

During this webcast, the expert faculty discussed:

 

  • When to consider GW CBD
  • The importance of diagnosis: LGS in adult patients
  • Managing adverse events associated with GW CBD
  • Determining the optimal dose of GW CBD 
  • Initiating GW CBD in patients who have tried or who are currently receiving non-regulatory approved cannabis-based products
  • Early versus late intervention with GW CBD
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020

../assets/websitedata/webcast.gw-pharma.com/Files/HEL-153806-EpilepsyFocusWebcast3-V3a.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 2 September 2020

All

0

>

Welcome, introduction and agenda

258

Initiating patients with GW CBD (case studies)

960

Initiating patients with GW CBD (discussion)

1210

Polytherapy and monitoring requirements with GW CBD (presentation and case study)

1908

Polytherapy and monitoring requirements with GW CBD (discussion)

2164

From paediatric to adolescent/adult care (case studies)

2772

From paediatric to adolescent/adult care (discussion)

3081

Epilepsy care and implications for GW CBD treatment in the times of COVID-19 (panel discussion)

4198

Meeting close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 2 September 2020

During this webcast, the expert faculty discussed: 

 

  • Identifying patients that might benefit from GW CBD
  • Reintroducing clobazam in patients who have previously tried and discontinued clobazam
  • Polytherapy and monitoring requirements
  • Transition from paediatric to adolescent/adult care
  • Epilepsy care and implications for GW CBD treatment in the times of COVID-19
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 2 September 2020

https://epilepsy-focus.co.uk/assets/websitedata/webcast.gw-pharma.com/Files/webcast_2.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 2 July 2020

All

0

>

Welcome and introduction

270

GW CBD patient profile (case studies)

677

GW CBD patient profile (discussion)

1154

Starting and maintaining patients on GW CBD (case studies)

1627

Starting and maintaining patients on GW CBD (discussion)

2084

Managing adverse events (case studies)

2637

Managing adverse events (discussion)

3031

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (case studies)

3633

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (discussion)

4015

General open discussion

4403

Summary and close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 2 July 2020

During this webcast, the expert faculty discussed:

 

  • GW CBD patient profile 
  • Starting and maintaining patients on GW CBD
  • Managing adverse events associated with GW CBD 
  • GW CBD in patients who have tried or who are currently receiving unlicensed cannabis-based products
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 2 July 2020

../assets/websitedata/webcast.gw-pharma.com/Files/webcast_1.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 4 June 2020

All

0

>

Welcome and introduction

285

GW CBD patient profile (case studies)

710

GW CBD patient profile (discussion)

1164

Starting and maintaining patients on GW CBD (case studies)

1683

Starting and maintaining patients on GW CBD (discussion)

2137

Managing adverse events (case studies)

2628

Managing adverse events (discussion)

3049

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (case studies)

3649

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (discussion)

4446

Summary and close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 4 June 2020

During this webcast, the expert faculty discussed:

 

  • GW CBD patient profile 
  • Starting and maintaining patients on GW CBD
  • Managing adverse events associated with GW CBD 
  • GW CBD in patients who have tried or who are currently receiving unlicensed cannabis-based products
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 4 June 2020

E-Learning videos

/ClientData/113/407/334886/2913/4/Epilepsy Focus_Shared clinical experience_Richard Chin_Approved.mp4

Challenges and solutions in managing children with refractory epilepsy (during the COVID-19 pandemic)

Richard FM Chin

0

Welcome and introduction

94

Challenges and solutions for diagnosis

416

Virtual platforms: NHS Near Me

476

Requirements and limitations of virtual consults

707

Virtual platforms: vCreate

1001

Challenges and solutions for monitoring

1171

Challenges and solutions for treatment

1425

Now and the future

Challenges and solutions in managing children with refractory epilepsy (during the COVID-19 pandemic)

Challenges and solutions in managing children with refractory epilepsy 
(during the COVID-19 pandemic)

 

Professor Richard FM Chin talks about the challenges his team faced during the COVID-19 pandemic and solutions they developed to facilitate remote consultations and monitoring, including vCreate, a cloud-based bidirectional video interface. 

Register / Log in to watch
Challenges and solutions in managing children with refractory epilepsy (during the COVID-19 pandemic)

/ClientData/113/407/226980/2913/4/HEL-153563-Webcast-NickJonesV6.mp4

Cannabinoid science

Nick Jones

0

Introduction and agenda

44

History and overview

260

Physicochemical properties

348

Cannabis and cannabinoid terminology: disambiguation

423

Mechanism of action

Cannabinoid science

Nick Jones discusses developments in cannabinoid medical research, regulatory vs non-regulatory approved cannabis-based products, and the molecular pharmacology and proposed mechanism of action of CBD in epilepsy. 

Register / Log in to watch
Cannabinoid science

/ClientData/113/407/226979/2913/4/Epilepsy Focus_Video_Clinical Management_Bernhard Steinhoff_compressed.mp4

Clinical management

Bernhard Steinhoff

0

Introduction

32

Clinical management of Lennox-Gastaut syndrome

511

Clinical management of Dravet syndrome

892

Transition to adolescence and adulthood

Clinical management

Professor Bernhard Steinhoff discusses the journey of patients with LGS and DS from childhood to adulthood, including age-related treatment considerations and challenges for caregivers and neurologists. 

Register / Log in to watch
Clinical management

/ClientData/113/407/315216/2913/4/LMR-intro.mp4

Shared clinical experience: introduction

Shared clinical experience: introduction

Register / Log in to watch
Shared clinical experience: introduction

/ClientData/113/407/314939/2913/4/EpilepsyFocus_CBD_patient_profile_Elizabeth Thiele_video.mp4

Shared clinical experience: GW CBD patient profile

Elizabeth Thiele

Shared clinical experience: GW CBD patient profile

Professor Elizabeth Thiele presents the clinical case of a 22-year-old patient that aims to illustrate the GW CBD patient profile.

Register / Log in to watch
Shared clinical experience: GW CBD patient profile

/ClientData/113/407/314946/2913/4/EpilepsyFocus_Shared_clinical_experience_case_study_AngelaKaindl_video.mp4

Shared clinical experience: starting and maintaining patients on GW CBD (part 1)

Angela M Kaindl

Shared clinical experience: starting and maintaining patients on GW CBD (part 1)

Professor Angela Kaindl describes starting and maintaining patients on GW CBD using an illustrative clinical case of a 13-year-old patient.

Register / Log in to watch
Shared clinical experience: starting and maintaining patients on GW CBD (part 1)

/ClientData/113/407/314948/2913/4/EpilepsyFocus_Start_and_maintain_on_CBD_SelimBenbadis_video.mp4

Shared clinical experience: starting and maintaining patients on GW CBD (part 2)

Selim Benbadis

Shared clinical experience: starting and maintaining patients on GW CBD (part 2)

Professor Selim Benbadis describes the clinical case of a 25-year-old patient to illustrate starting and maintaining patients on GW CBD.

Register / Log in to watch
Shared clinical experience: starting and maintaining patients on GW CBD (part 2)

/ClientData/113/407/314949/2913/4/EpilepsyFocus_Managing_adverse_events_ElizabethThiele_video.mp4

Shared clinical experience: managing adverse events

Elizabeth Thiele

Shared clinical experience: managing adverse events

Professor Elizabeth Thiele presents a clinical case to demonstrate her management of adverse effects including lethargy and elevated liver function tests in a 19-year-old patient receiving GW CBD.

Register / Log in to watch
Shared clinical experience: managing adverse events

/ClientData/113/407/314955/2913/4/EpilepsyFocus_OtherCBD_products_SelimBenbadis_video.mp4

Shared clinical experience: patients who have tried or are currently receiving non-regulatory approved cannabis-based products

Selim Benbadis

Shared clinical experience: patients who have tried or are currently receiving non-regulatory approved cannabis-based products

Professor Selim Benbadis discusses how GW CBD might be introduced in a patient who is currently receiving non-regulatory approved cannabis-based products through an illustrative clinical case study of a 7-year-old patient.

Register / Log in to watch
Shared clinical experience: patients who have tried or are currently receiving non-regulatory approved cannabis-based products
For more information about Epidyolex®, please refer to the Epidyolex® summary of product characteristics and/or the Epidyolex® website for UK Healthcare Professionals.

© Copyright GW Pharmaceuticals 2020
This website is intended for healthcare professionals only. If you are not a healthcare professional, please visit www.gwpharm.co.uk
VV-MED-16326
Date of Preparation: December 2020

Login

Already registered?
Log in using your email address.

REGISTER

New to this platform?
Click below to register and to gain access to our on-demand videos and Epidyolex® (cannabidiol) shared experience webcasts.
Register now

Register for our Epidyolex®(cannabidiol) shared experience webcasts

Enter your details below to register. Did you already register? Click here to login.

Personal info *

Webcast info

Legal info

Your consent to receive educational / marketing information and communications.

Applicable laws may require GW Pharmaceuticals to obtain your specific consent in order to contact you by email or other electronic means, and by non-electronic means, with educational and marketing information and communications about GW Pharmaceuticals and its products, and meetings run by or on behalf of GW Pharmaceuticals, that we feel may be of interest to you. Providing your consent to GW Pharmaceuticals to send educational / marketing information and communications is voluntary. You may withdraw your consent at any time by sending an email to unsubscribe@gwpharm.com. Should you withdraw your consent, it may prevent GW Pharmaceuticals from sending you further information or communications, although GW Pharmaceuticals may be required or entitled to continue to process your personal data in order to comply with its legal and regulatory obligations and to protect its legal rights and interests, but at all times, such processing will be in accordance with the Privacy Notice.

Next step

Thanks for registering

Thanks for registering. Please check your email to verify your account. If you don't receive this email shortly, please check your spam folder.

The email will contain further instructions.

Thanks for submitting a question

Thank you for submitting your question.

All questions will be collated and directed to the relevant speaker(s) for discussion in the live webcasts.
 

Welcome to the GW Pharmaceuticals Epilepsy Focus microsite!

This microsite is intended for UK healthcare professionals or German healthcare professional prescribers only.
Please confirm that you are a registered UK healthcare professional or German healthcare professional prescriber.





Welcome to GW Pharmaceuticals Epilepsy Focus microsite!

Thank you for visiting our microsite.

Please note that this microsite is only accessible to UK healthcare professionals and German healthcare professional prescribers.
For more information about GW Pharmaceuticals, please visit our corporate website.

 
 

You are about to leave this website

Please note this link will redirect you to an external website.

Please confirm if you are happy to continue.

Please note this link will redirect you to an external website.

Please confirm if you are happy to continue.

Continue Cancel
 
 

CONFIRM YOUR EMAIL ADDRESS

Thank you for completing this form. Please note that you are not yet fully registered. You will receive an email to your email address from noreply@epilepsy-focus.co.uk with a confirmation link. In order to complete the registration process and gain full access to our e-learning videos and webcasts, please click the link in your confirmation email.

If you do not receive a confirmation email, please check your spam folder. Also, please verify that you entered a valid email address in our sign-up form.

If you need assistance, please contact support-focus@gwpharm.com

I Understand
 
 

THANKS FOR SUBMITTING A QUESTION

Thank you for submitting your question.

All questions will be collated and directed to the relevant speaker(s) for discussion in the live webcasts.

Close
 
Please use a larger browser window for a better website experience.